incredible, page-33

Dhukka, as an aside, I interpret the following differently.
you say -
"as the company states the cash will be used for cellucreme and the "commencement of phase 2 Oxy"."


The anny says -

"Future Financing and Operational cashflow will be primarily directed to the launch of the anticellulite
product in April, the completion of a commercial oxycodone patch and the commencement of a Phase 2 study in the third quarter."

I am not sure that the completion of a commercial oxy patch and the phase 2 study statement is neccessarily about the same thing.
This phase 2 study could mean for either of 3 products that could be ready for phase 2, in order - diclofenac, lidocaine or retinoic.

Also - the announcement might mean that the completion of oxy patch may be financed by the "partner" and not by money raised by placement.
It doesn't make it clear either way, but it certainly doesn't suggest that oxy patch will have to be funded solely by POH.
It all will come down to what "future financing" actually means.